ClinicalTrials.Veeva

Menu

A Study to Evaluate the Safety, Tolerability and Efficacy of Intravenous TAK-573 as Part of Combination Therapy in Participants With Relapsed or Refractory Multiple Myeloma (RRMM)

Takeda logo

Takeda

Status and phase

Withdrawn
Phase 1

Conditions

Relapsed and/or Refractory Multiple Myeloma

Treatments

Drug: TAK-573
Drug: Dexamethasone
Drug: Cyclophosphamide
Drug: Bortezomib
Drug: Pomalidomide

Study type

Interventional

Funder types

Industry

Identifiers

NCT04392648
U1111-1249-1537 (Registry Identifier)
TAK-573-1002

Details and patient eligibility

About

The purpose of this study is to determine the safety, tolerability, and recommended phase 2 dose (RP2D) of TAK-573 when used with dexamethasone and in combination with bortezomib, pomalidomide, or cyclophosphamide, in participants with RRMM.

Full description

The drug that is being tested in this study is called TAK-573. The study will evaluate the safety, tolerability, pharmacokinetics (PK) and pharmacodynamics (PD) of TAK-573 when used in combination with dexamethasone and either bortezomib, pomalidomide or cyclophosphamide in participants with RRMM.

The study will be conducted in 2 phases: Dose Escalation Phase and Dose Expansion Phase. The study will enroll approximately 135 participants (approximately 60 participants in Dose Escalation Phase and approximately 75 participants in Dose Expansion Phase). The dose escalation phase will determine the recommended dose of TAK-573 along with the combination agents for the dose expansion phase.

This multi-center trial will be conducted in the United States, Germany, France, Spain, and Canada. The overall time to participate in this study is approximately 3 years. Participants will be followed up for 30 days after the last dose of study drug for a follow-up assessment.

Sex

All

Ages

18+ years old

Volunteers

No Healthy Volunteers

Inclusion criteria

  1. Received >=2 prior lines of therapy, including treatment with lenalidomide and a proteasome inhibitor.

  2. Have an Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1.

  3. With measurable disease, defined as at least 1 of the following:

    • Serum M protein >=500 mg/dL (>=5 gram per liter [g/L]) on serum protein electrophoresis (SPEP).
    • Urine M protein >=200 mg/24 hours on urine protein electrophoresis (UPEP).
    • Serum FLC assay result with an involved FLC level >=10 mg/dL (>=100 milligram per liter [mg/L]), provided the serum FLC ratio is abnormal.
  4. Has adequate organ function as determined by the following laboratory values:

    • Absolute neutrophil count (ANC) >=1000 per cubic millimeter (/mm^3) (>=1.0*10^9 [per liter]/L)
    • Platelets >=75,000/mm^3 (>=75*10^9/L)
    • Hemoglobin >=80 g/L
    • Creatinine clearance >=30 milliliter per minute (mL/min)
    • Total serum bilirubin <=1.5*upper limit normal (ULN), >=2.0*ULN for participants with Gilbert's syndrome
    • Liver transaminases (alanine aminotransferase [ALT]/ aspartate aminotransferase [AST]) Serum ALT or AST <=3.0*ULN (<5*ULN if enzyme elevations are due to MM-related diffuse hepatic infiltrations).
  5. Has received the final dose of any of the following treatments/procedures within the specified minimum intervals before first dose of TAK-573:

    • Chemotherapy, including proteasome inhibitors and immunomodulatory imide drug.(IMiDs) 14 days
    • Antimyeloma antibody therapy 21 days
    • Corticosteroid therapy for myeloma 7 days
    • Radiation therapy for localized bone lesions 7 days
    • Major surgery 21 days.

Exclusion criteria

  1. Has polyneuropathy, organomegaly, endocrinopathy, monoclonal gammopathy and skin changes (POEMS) syndrome, monoclonal gammopathy of unknown significance, smoldering myeloma, solitary plasmacytoma, amyloidosis, Waldenström macroglobulinemia or IgM myeloma, lymphoplasmacytic lymphoma, or plasma cell leukemia.
  2. Previous intolerance to combination agent.
  3. For the pomalidomide expansion group only: no prior treatment with pomalidomide.
  4. Inability to take prophylaxis needed for combination agent (deep vein thrombosis prophylaxis for pomalidomide, antiviral prophylaxis for proteasome inhibitor).
  5. Who have received autologous stem cell transplant (SCT) within 60 days before first infusion of TAK-573 or participants who have received allogeneic SCT 6 months before first infusion. Graft-versus-host disease that is active or requires ongoing systemic immunosuppression.
  6. Has not recovered from adverse reactions to prior myeloma treatment or procedures (chemotherapy, immunotherapy, radiation therapy) to NCI CTCAE Grade <=1 or baseline, except for sensory or motor neuropathy which should have recovered to Grade <=2 or baseline, Grade <2 for participants receiving bortezomib.
  7. Has a chronic condition requiring the use of systemic corticosteroids >10 milligram per day (mg/day) of prednisone or equivalent.

Trial design

Primary purpose

Other

Allocation

Non-Randomized

Interventional model

Sequential Assignment

Masking

None (Open label)

0 participants in 6 patient groups

Escalation:TAK-573 0.1-1.5mg/kg+Bortezomib+Dexamethasone
Experimental group
Description:
TAK-573 0.1 to 1.5 milligram per kilogram (mg/kg), infusion, intravenously, once, every 3 weeks in a 21-days treatment cycle, along with bortezomib 1.3 milligram per square meter (mg/m^2), injection, subcutaneously, once on Days 1, 4, 8, and 11 and dexamethasone 40 milligram (mg) (20 mg if aged more than 75 years), tablets, orally on Days 1, 8, and 15 in each 21-days treatment cycle from Cycle 1 through Cycle 8. For participants who continue beyond Cycle 8, TAK-573 will be given as an infusion, intravenously, once, every 3 weeks in a 21-days treatment cycle with dexamethasone 40 mg (20 mg if aged more than 75 years), tablets, orally from Cycle 9 through Cycle 17.
Treatment:
Drug: Bortezomib
Drug: Dexamethasone
Drug: TAK-573
Escalation:TAK-573 0.05-0.75mg/kg+Pomalidomide+Dexamethasone
Experimental group
Description:
TAK-573 0.05 to 0.75 mg/kg, infusion, intravenously, once, every 4 weeks in a 28-days treatment cycle, along with pomalidomide 4 mg, capsules, orally, once daily from Days 1 through 21 and dexamethasone 40 mg (20 mg if aged more than 75 years), tablets, orally, once on Days 1, 8, 15, and 22 in each 28-days treatment cycle from Cycle 1 through Cycle 17.
Treatment:
Drug: Pomalidomide
Drug: Dexamethasone
Drug: TAK-573
Escalation:TAK-573 0.1-1.5mg/kg+Cyclophosphamide+Dexamethasone
Experimental group
Description:
TAK-573 0.1 to 1.5 mg/kg, infusion, intravenously, once, every 4 weeks in a 28-days treatment cycle, along with cyclophosphamide 300 mg/m^2, tablets, orally, once on Days 1, 8, and 15 and dexamethasone 40 mg (20 mg if aged more than 75 years), tablets, orally, once on Days 1, 8, 15, and 22 in each 28-days treatment cycle from Cycle 1 through Cycle 17.
Treatment:
Drug: Cyclophosphamide
Drug: Dexamethasone
Drug: TAK-573
Expansion: TAK-573 + Bortezomib + Dexamethasone
Experimental group
Description:
TAK-573, infusion, intravenously, once, every 3 weeks in a 21-days treatment cycle, along with bortezomib 1.3 mg/m^2, injection, subcutaneously, once on Days 1, 4, 8, and 11 and dexamethasone 40 mg (20 mg if aged more than 75 years), tablets, orally, once on Days 1, 8, and 15 in each 21-days treatment cycle until disease progression, intolerable toxicity, withdrawal from study, or death (up to 3 years). The dose of TAK-573 for Dose Expansion Phase will be the RP2D and recommended dose for expansion (RAD) determined in the previous Dose Escalation Phase.
Treatment:
Drug: Bortezomib
Drug: Dexamethasone
Drug: TAK-573
Expansion: TAK-573 + Pomalidomide + Dexamethasone
Experimental group
Description:
TAK-573, infusion, intravenously, once, every 4 weeks in a 28-days treatment cycle, along with pomalidomide 4 mg, capsules, orally, once daily from Days 1 through 21 and dexamethasone 40 mg (20 mg if aged more than 75 years), tablets, orally, once on Days 1, 8, 15, and 22 in each 28-days treatment cycle until disease progression, intolerable toxicity, withdrawal from study, or death (up to 3 years). The dose of TAK-573 for Dose Expansion Phase will be the RP2D and RAD determined in the previous Dose Escalation Phase.
Treatment:
Drug: Pomalidomide
Drug: Dexamethasone
Drug: TAK-573
Expansion: TAK-573 + Cyclophosphamide + Dexamethasone
Experimental group
Description:
TAK-573, infusion, intravenously, once, every 4 weeks in a 28-days treatment cycle, along with cyclophosphamide 300 mg/m^2, tablets, orally, once on Days 1, 8, and 15 and dexamethasone 40 mg (20 mg if aged more than 75 years), tablets, orally, once on Days 1, 8, 15, and 22 in each 28-days treatment cycle until disease progression, intolerable toxicity, withdrawal from study, or death (up to 3 years). The dose of TAK-573 for Dose Expansion Phase will be the RP2D and RAD determined in the previous Dose Escalation Phase.
Treatment:
Drug: Cyclophosphamide
Drug: Dexamethasone
Drug: TAK-573

Trial contacts and locations

0

Loading...

Data sourced from clinicaltrials.gov

Clinical trials

Find clinical trialsTrials by location
© Copyright 2024 Veeva Systems